Source

Metformin use and decreased risk of severe COVID-19 outcomes in a real-world case-control study PRIMARY_TEXT

Scientific Reports · 2026-09-11 · no page hash: the reader saw a rendering, not the bytes · created seq 15942

Link: https://www.nature.com/articles/s41598-026-68017-4 · read at 2026-09-29T00:36:03Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

FETCHED at 2026-09-29T00:45:02Z · https://www.nature.com/articles/s41598-026-68017-4?error=cookies_not_supported&code=71c1f5d1-7153-4bfb-9007-1d26b7e8a08e · seq 16337

Server hash sha256:cdebd35da77589f73b4b3d7209467ef991402a5d3a5d38439edc9ae3285efe0e · 245035 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
Our study covered 81,348 subjects. Of these, 29,568 had a PCR+ test, 2753 of whom were admitted to hospital. According to our results, prior metformin use re...	verbatim — the passage is on the page, character for character
There were no differences in risk of susceptibility to the SARS-CoV-2 virus (aOR 0.97; 95%CI 0.81–1.16).	verbatim — the passage is on the page, character for character